AP718A - A controlled-release pharmaceutical formulation for oral administration. - Google Patents
A controlled-release pharmaceutical formulation for oral administration. Download PDFInfo
- Publication number
- AP718A AP718A APAP/P/1996/000883A AP9600883A AP718A AP 718 A AP718 A AP 718A AP 9600883 A AP9600883 A AP 9600883A AP 718 A AP718 A AP 718A
- Authority
- AP
- ARIPO
- Prior art keywords
- formulation
- molecular weight
- polyethylene oxide
- range
- hydroxypropylmethyl cellulose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a controlled-release pharmaceutical formulation for oral administration consisting essentially of: an active drug compound; low molecular weight polyethylene oxide; hydroxypropylmethyi cellulose; tabletting excipients; and optionally one or more enteric polymers. Formulations according to the invention produce a constant rate of release of drug in in vitro models of the gastrointestinal tract.
Description
Pharmaceutical formulations
This invention relates to controlled-release oral pharmaceutical formulations.
Controlled-release oral pharmaceutical formulations are known. Their purpose is to modify the rate of drug release, for example to produce a constant rate of release of a drug into the gastrointestinal tract of a patient, or to delay the release of a drug into the gastrointestinal tract of a patient (see ‘Sustained and Controlled Release Drug Delivery Systems’, pp 3-6, edited by J R Robinson, published by Marcel Dekker Inc).
US Patent N° 4,765,989 discloses an osmotic delivery device for delivering inter alia nifedipine. or doxazosin. It has a perforated semipermeable wall enclosing a drug · κ composition which includes an osmopolymer, and a pusher composition containing a c second osmopolymer. The performance of this prior art device is satisfactory, but it has ~ the disadvantage that it is very complicated, leading to high manufacturing costs. c
UK Patent Application 2,123,291 discloses a sustained release formulation of. suloctidil which is a two-part tablet: a first part is a prompt-release portion and a second part is a slow-release portion, which must contain a surface-active agent to promote bio-erosion.
US Patent N° 5,393,765 discloses an erodible pharmaceutical composition providing a zero order controlled release profile, comprising low viscosity hydroxypropylmethyl cellulose.
According to the present invention, there is provided a controlled-release pharmaceutical formulation for oral administration consisting essentially of: an active drug compound; low molecular weight polyethylene oxide; hydroxypropylmethyl cellulose; tabletting excipients; and optionally one or more enteric polymers.
0 Primarily, oral administration” means administration to the mouth followed by swallowing. However, the formulations of the present invention may also be administered buccally (i.e. placed behind the top lip and allowed to dissolve), and the term includes such formulations.
AP.0 0 7 1 8 “Consisting essentially of means that at least 95% by weight of the formulation is made up of the listed components. At least 99% by weight of uncoated formulations, and the cores of coated formulations, are preferably made up of the listed components.
Polymerized ethylene oxide having a number average molecular weight less than 100,000 is sometimes referred to as polyethylene glycol. However, for simplicity, the term “low molecular weight polyethylene oxide” is used to refer to polymerized ethylene oxide in the number average molecular weight range of interest, namely 15,000 to 750,000.
Tabletting excipients making up formulations according to the invention may be conventional tabletting excipients, for example dibasic calcium phosphate, lactose and magnesium stearate. · b c c
There are three classes of drug compound which are particularly suitable for administra- c 15 tion in formulations according to the invention. The first class is weakly basic compounds. c •fc.
Examples of this class include dipyridamole, noscapine, papaverine, doxazosin, sildenafil »
and prazosin. Doxazosin and its pharmaceutically acceptable salts are of particular c interest.
0 The second class are compounds having high solubility in aqueous media. Examples of this class include salbutamol, metoprolol, propanolol, aminophylline, isosorbide monoand dinitrate, glyceryl trinitrate, verapamil, captopril, diltiazem, morphine, chlorpheniramine, promethazine, eletriptan, darifenacin and fluconazole.
5 The third class are compounds having low solubility in aqueous media. Examples of this class include nifedipine, griseofulvin, carbamazepine, felodipine, nimodipine and megestrol.
The terms high solubility in aqueous media” and “low solubility in aqueous media” will be
0 understood by those skilled in the art. However, the former may be defined as a solubility >1mg/ml in water, and the latter may be defined as a solubility <1mg/ml in water.
It will be apparent to those skilled in the art that some compounds may fall into more than one of the above classes, for example certain compounds may be weakly basic and have
5 a high solubility in aqueous media.
AP 00718
Formulations according to the invention have the advantage that they produce a constant rate of release of drugs that are weakly basic and/or have a high solubility in aqueous media in in vitro models of the gastrointestinal tract, and so are expected to produce a constant rate of release of the drug in the gastrointestinal tract of a patient. When the drug to be administered has a low solubility in aqueous media, the formulations of the invention have the advantage that they produce a delayed or pulsed release of the drug. However, the formulations are very simple and so can be manufactured at a comparatively low cost.
Preferably, the hydroxypropylmethyl cellulose has a number average molecular weight in the range 80,000-250,000. Preferably, the hydroxypropylmethyl cellulose has a degree of methy! substitution in the range 19-30 %. Preferably, the hydroxypropylmethyl cellulose has a degree of hydroxy substitution in the range 4-12 %. A number of hydroxypropylme15 thyl cellulose polymers are available commercially under the brand name Methocel®, and some of those suitable for use in formulations according to the invention are given in the table below:
Methocel® grade | Number average MVV | Degree of methyl substitution | Degree of . hydroxy substitution | Nominal viscosity of a 2% aqueous solution | USP designation |
K4M | 89000 | 19-24% | 4-12% | 4000cps | 2208 |
K15M | 125000 | u | II | 15000cps | II |
K100M | 215000 | u | 100000cps | II | |
E4M | 93000 | 28-30% | 7-12% | 4000cps | 2910 |
E10M | 113000 | u | II | 10000cps | II |
F4M | 90000 · | 27-30% | 4-7.5% | 4000cps | 2906 |
0 Methocel® K4M has characteristics of particular interest.
• Preferably, the low molecular weight polyethylene oxide has a number average molecular weight in the range 20,000 to 500,000, more preferably 100,000-300,000. Polyethylene oxide with a number average molecular weight above 100,000 is a powder, which makes it easier to handle than lower molecular weight polyethylene oxide, which has a lower melting point. For example, polyethylene oxide with a number average molecular weight of 6000 has a melting point of 60-63°C.
AP . Ο Ο 7 1 8
It will be apparent to those skilled in the art that the polyethylene oxide may consist of molecules of different chain lengths, but that the average chain length gives a molecular weight in the range stated. The same applies to the hydroxypropylmethyl cellulose.
Formulations according to the invention may contain an enteric polymer admixed with the other components of the formulation. In addition or alternatively, formulations according to the invention are preferably provided with a coating of an enteric polymer. Enteric polymers that may be mentioned are phthalate derivatives (including cellulose acetate phthalate, polyvinylacetate phthalate and hydroxypropylmethyl cellulose phthalate), polyacrylic acid derivatives (including methacrylic acid copolymer), and vinyl acetate and crotonic acid copolymers. Methacrylic acid copolymer is of particular interest.
. i
Preferably, the formulation contains up to 50% by weight of active drug compound, for example 1-20%.
It is preferred that the formulations of the invention contain 5-30% by weight of low molecular.weight polyethylene oxide, for example 8-10%.
Preferably, the formulations of the invention contain 10-60% by weight of hydroxypropyl20 methyl cellulose, for example 25-35%.
Formulations having enteric polymer admixed with the other components of the formulation preferably have 10-40% by weight of admixed enteric polymer, for example 25-35%.
5 In formulations according to the present invention, it is preferred that the mass ratio of low molecular weight polyethylene oxide:hydroxypropylmethyl cellulose is in the range 2:11:5.
in formulations according to the present invention containing admixed enteric polymer, it
0 is preferred that the mass ratio of (low molecular weight polyethylene oxide+hydroxypropylmethyl cellulose):admixed enteric polymer is in the range 1:2-6:1, more preferably 1:2-2:1. Preferably, the enteric coating (where present) makes up 2-15% by weight of the formulation, more preferably 5-10% by weight of the formulation.
AP.00718
According to another aspect of the invention, there is provided the use of low molecular weight polyethylene oxide in an oral controlled-release pharmaceutical formulation, having a hydroxypropylmethyl cellulose matrix, to enhance the erosion of the matrix after a predetermined period of time following administration of the formulation to a patient.
Typically, the predetermined period of time is 6 hours. In this way, a constant rate of drug release can be achieved in the gastrointestinal tract of a patient despite the varying conditions which exist along its length.
By varying the proportion of polyethylene oxide in the formulation it is possible to control 10 the onset of enhancement of matrix erosion and so the onset of increased drug release following administration of the formulation to a patient.
cc
According to a yet further aspect of the invention, there is provided a process for the c production of a pharmaceutical formulation as defined in claim 1, which comprises mixing: ° an active drug compound; low molecular weight polyethylene oxide; hydroxypropylmethyl cellulose; tabletting excipients; and optionally one or more enteric polymers; followed by cn pressing into tablets. ς *
The drug release properties of formulations according to the present invention may be
0 measured in a model of the gastrointestinal tract such as Apparatus 1 of USP 22, page
1578, Method 1 (baskets).
The invention is illustrated by the following examples with reference to the accompanying drawings, in which:
Figure 1 shows the percentage of drug compound released v time from formulations according to the invention [as prepared in Examples 1(a) and 1(b)] in comparison with a control [as prepared in Example 6] using simple dissolution testing; and
Figure 2 shows the percentage of drug compound released v time from a formulation • according to the invention [as prepared in Example 2(a)] using dissolution testing with first
0 an acidic and then a neutral dissolution medium.
Example 1
Sustained release formulations of doxazosin mesylate (a)
Ingredient mg/tablet
AP . Ο Ο 7 1 8
Doxazosin mesylate3 | 3.636 |
Polyethyleneoxide 100,000 MW° | 9.000 |
Polyethyleneoxide 200,000 MW2 | 9.000 |
Hydroxypropylmethylcellulose0 | 60.000 |
Dibasic calcium phosphate® | 58.182 |
Lactose' | 58.182 |
Magnesium stearate | 2.000 |
Total | 200.000 |
a equivalent to 3mg doxazosin based on a theoretical activity of 82.5% b as Polyox® WSR N 10 c as Polyox® WSR N 80 d as Methocel® K4M e as anhydrous f as lactose fast flo cc
All of the ingredients except the magnesium stearate were blended together in a Turbula
C.Z blender for 10 minutes. The mixture was then screened using a 30 mesh (500pm t— apertures) screen and reblended for a further 10 minutes. Then the magnesium stearate
CC was screened through a 30 mesh (500pm apertures) screen and added to the mixture
GT before blending for a further 5 minutes. The blend was then subjected to compression on a tabletting machine using 8mm round normal convex tooling to make the required number of tablets of 200 mg mass.
(b)
Ingredient | mg/tablet |
Doxazosin mesylate3 | 4.876 |
Polyethyleneoxide 100,000 MW° | 20.000 |
Polyethyleneoxide 200,000 MW° | 20.000 |
Hydroxypropylmethylcellulose0 | 60.000 |
Dibasic calcium phosphate® | 46.562 |
Lactose' | 46.562 |
Magnesium stearate | 2.000 |
Total | 200.000 |
a equivalent to 4mg doxazosin based on a theoretical activity of 82.5% 2 0 b as Polyox® WSR N 10 c as Polyox® WSR N 80 d as Methocel® K4M e as anhydrous f as lactose fast flo
200mg tablets were prepared by the method of (a).
AP.00718 (C)
Ingredient | mg/tablet |
Doxazosin mesylate3 | 4.876· |
Polyethyleneoxide 100,000 MW° | 30.000 |
Polyethyleneoxide 200,000 MW° | 30,000 |
Hydroxypropylmethylcellulose0 | 60.000 |
Dibasic calcium phosphate6 | 36.562 |
Lactose' | 36.562 |
Magnesium stearate | 2.000 |
Total | 200.000 |
a equivalent to 4mg doxazosin based on a theoretical activity of 82.5%
b | as Polyox® WSR N 10 | |
c | as Polyox® WSR N 80 | |
d | as Methocel® K4M | |
e | as anhydrous | . ro |
f | as lactose fast flo | co |
co | ||
200mg tablets were prepared by the method of (a). | CO | |
o | ||
Examole 2 | co | |
Sustained release formulations of doxazosin mesvlate containinq an enteric oolvmer | CD |
Ingredient | mg/tablet |
Doxazosin mesylate3 | 3.636 |
Polyethyleneoxide 100,000 MW° | 9.000 |
Polyethyleneoxide 200,000 MW6 | 9.000 |
Hydroxypropylmethylcellulose0 | 60.000 |
Methacrylic acid copolymer type6 C | 60.000 |
Dibasic calcium phosphate1 | 28.182 |
Lactose9 | 28.182 |
Magnesium stearate | 2.000 |
Total | 200.000 |
a equivalent to 3mg doxazosin based on a theoretical activity of 82.5% b as Polyox® WSR N 10 c as Polyox® WSR N 80 d as Methocel® K4M e as Eudragit® L 100 55 f as anhydrous g as lactose fast flo
200mg tablets were prepared by the method of Example 1(a).
(b)
AP . Ο Ο 7 1 8
Ingredient | mg/tablet |
Doxazosin mesylate3 | 4.876 |
Polyethyleneoxide 100,000 MW° | 20.000 |
Polyethyieneoxide 200,000 MW^ | 20.000 |
Hydroxypropylmethylcellulose0 | 60.000 |
Methacrylic acid copolymer type C® | 60.000 |
Dibasic calcium phosphate' | 16.562 |
Lactose9 | 16.562 |
Magnesium stearate | 2.000 |
Total | 200.000 |
a equivalent to 4mg doxazosin based on a theoretical activity of 82.5% b as Polyox® WSR N 10 c as Polyox® WSR N 80 d as Methocel® K4M e as Eudragit® L 100 55 f as anhydrous g as lactose fast fio
200mg tablets were prepared by the method of Example 1(a).
Example 3
Sustained release formulations of doxazosin mesylate having an enteric coat (a)
Ingredient | mg/unit |
Doxazosin mesylate tablets from Example 1(a) | 200.000 |
Methacrylic acid copolymer type | 6.500 |
Triethyl citrate | 0.650 |
Talc | 3.250 |
Sodium hydroxide | 0.090 |
Purified Water0 | (41.510) |
Total | 210.490 |
a as Eudragit® L 100-55 b Lost during processing and does not appear in the final product
Al! of the ingredients except the tablets were mixed together until the methacrylic acid copolymer had dispersed. This mixture was then applied to the tablets by spraying to give a coating of the required weight using conventional means.
(b)
ingredient | mg/unit |
Doxazosin mesylate tablets from Example 2(a) | 200.000 |
K0 co co co to
CD x
3«
Methacrylic acid copolymer type Ca | 6.500 |
Triethyl citrate | 0.650 |
Talc | 3.250 |
Sodium hydroxide | 0.090 |
Purified Water0 | (41.510) |
Total | 210.490 |
a as Eudragit® L 100-55' b Lost during processing and does not appear in the final product
The tablets were coated by the method of (a).
(c)
Ingredient | mg/unit |
Doxazosin mesylate tablets from Example 2(a) | 200.000 |
Methacrylic acid copolymer type Aa | 3.985 |
Methacrylic acid copolymer type B° | 3.985 |
Triethyl citrate | 3.984 |
Ammonia solution0 | 0.058 |
Water content of ammonia solution0 | (0.172) |
Talc | 3.988 |
Purified Water0 | (55.554) |
Total | 216.000 |
CC co a as Eudragit® L 100 b as Eudragit® S 100 c As ammonia solution sp.gr.0.91(25% NH3). The aqueous component of this solution is lost during processing.
d Lost during processing and does not appear in the final product o
<o co crf'-T a
<
The tablets were coated by the method of (a).
Example 4
Sustained release formulation of darifenacin hydrobromide
Ingredient | mg/tablet |
Darifenacin hydrobromide | 35.714 |
Polyethyleneoxide 100,000 MW° | 20.000 |
Polyethyleneoxide 200,000 MW° | 20.000 |
Hydroxypropylmethylcellulose0 | 60.000 |
Lactose6 | 62.286 |
Magnesium stearate | 2.000 |
Total | 200.000 |
AP.00718 a equivalent to 30mg darifenacin based on a theoretical activity of 84.0% b as Polyox® WSR N 10 c as Polyox® WSR N 80 d as Methocel® K4M e as anhydrous
200mg tablets were prepared by the method of Example 1(a).
Example 5
Sustained release formulations of fluconazole (suitable for buccal administration’) (a)
Ingredient | mg/tablet |
Fluconazole | 20.000 |
Polyethyleneoxide 100,000 MWa | 10.000 |
Polyethyleneoxide 200,000 MW5 | 10.000 |
Hydroxypropylmethylcellulose0 | 30.000 |
Lactose0 | 29.000 |
Magnesium stearate | 1.000 |
Total | 100.000 |
a as Polyox® WSR N 10 b as Polyox® WSR N 80 c as Methocel® K4M d as lactose fastflo
100mg tablets were prepared by the method of Example 1(a).
to co co
CC.:
co.
**·.
CD a
£·. «
0 (b)
Ingredient | mg/tablet |
Fluconazole | 10.000 |
Polyethyleneoxide 100,000 MWa | 7.500 |
Hydroxypropylmethylcellulose0 | 22.500 |
Dibasic calcium phosphate0 | 34.250 |
Magnesium stearate | 0.750 |
Total | 75.000 |
a as Polyox® WSR N 10 b as Methocel® K4M c as anhydrous
100mg tablets were prepared by the method of Example 1 (a).
Example 6 (Comparative)
Sustained release formulation of doxazosin mesylate not containing polyethvleneoxide
AP . Ο Ο 7 1 8
Ingredient | mg/tablet |
Doxazosin mesylate3 | 3.636 |
Hydroxypropylmethylcellulose0 | 60.000 |
Dibasic calcium phosphate0 | 67.182 |
Lactose0 | 67.182 |
Magnesium stearate | 2.000 |
Total | 200.000 |
a equivalent to 3mg doxazosin based on a theoretical activity of 82.5% b as Methocel® K4M c as anhydrous d as lactose fast flo
200mg tablets were prepared by the method of Example 1 (a).
co co
Example 7 o
Dissolution analysis o uo
The tablets of Examples 1(a), 1(b) and 6 were dissolved using Apparatus 1 of USP 22, page 1578, Method 1 (baskets). The dissolution fluid was 900ml of water at 37°C, the X t-^r-es rotation speed of the baskets was 100 rpm, and the drug compound released was hcira detected by UV spectroscopy at a wavelength of 246 nm. The percentage of drug compound released vtime for each tablet type is shown in Figure 1.
The tablets of Example 2(a) were dissolved using Apparatus 1 of USP 22, page 1578,
0 Method 1 (baskets). The dissolution fluid was 900ml of acidic medium [1M HCI, 100ml;
NaCI, 70.2g; water, to 10 litres; pH=2] at 37°C for 2 hours, which was then replaced with neutral pH medium [KH2PO4, 8.7g; KCI, 47.4g; NaCI, 20.3g; 1M NaOH, 52ml; water, to 10 litres] which was used for the remainder of the experiment. The rotation speed of the baskets was 200 rpm, and the drug compound released was detected by UV spectros25 copy at a wavelength of 246 nm. The percentage of drug compound released v time is shown in Figure 2.
Claims (25)
- Claims:Huiing now parnruJarh, Rented *ηΛ •ucctuncd cny/wr «a'iiKtnii.,0 and·!* vhn manner the same is tn iv. [rrheniei V.wc declMtc riiat whyr J.we claim » _1. A controlied-release pharmaceutical formulation for oral administration consisting essentially of: an active drug compound; low molecular weight polyethylene oxide;5 hydroxypropylmethyl cellulose; tabietting excipients; and optionally one or more enteric polymers.
- 2. A formulation as claimed in claim 1, wherein the active drug compound is weakly basic.
- 3. A formulation as claimed in claim 1 or claim 2, wherein the active drug compound is10 doxazosin, or a pharmaceutically acceptable salt thereof.
- 4. A formulation as claimed in claim 1, wherein the active drug compound has a high solubility in aqueous media.
- 5. A formulation as claimed in claim 1, wherein the active drug compound has a low solubility in aqueous media.15
- 6. ' A formulation as, claimed in any one of the preceding claims, wherein the hydroxypropyimethyl cellulose has a number average molecular weight in the range 80,000250,000.
- 7. A formulation as claimed in any one of the preceding claims, wherein the hydroxypropylmethyl cellulose has a degree of methyl substitution in the range 19-30 %.2 0
- 8. A formulation as claimed in any one of the preceding claims, wherein the hydroxypropylmethyl cellulose has a degree of hydroxy substitution in the range 4-12 %.
- 9. A formulation as claimed in any one of the preceding claims, wherein the polyethylene oxide has a number average molecular weight in the range 20,000-500,000.
- 10. A formulation as claimed in claim 9, wherein the polyethylene oxide has a number2 5 average molecular weight in the range 100,000-300,000.
- 11. A formulation as claimed in any one of the preceding claims, wherein an enteric polymer is admixed with the other components of the formulation,
- 12. A formulation as claimed in any one of the preceding claims, which has a coating containing an enteric poiymer.3 0
- 13. A formulation as claimed in claim 11 or claim 12, wherein the enteric polymer is methacrylic acid copolymer.
- 14. A formulation as claimed in any one of the preceding claims, which contains up to 50% by weight of active drug compound.
- 15. A formulation as claimed in any one of the preceding claims, which contains 5-30%3 5 by weight of low molecular Weight polyethylene oxide.rc co co oo to o
- 16. A formulation as claimed in any one of the preceding claims, which contains 10-60% by weight of hydroxypropylmethyl cellulose.
- 17. A formulation as claimed in any one of the preceding claims, which contains 10-40% by weight of enteric polymer by weight admixed with the other components of the5 formulation.
- 18. A formulation as claimed in any one of the preceding claims, wherein the mass ratio of low molecular weight polyethylene oxide:hydroxypropylmethyl cellulose is in the range 2:1-1:5.
- 19. A formulation as claimed in any one of claims 11-18, wherein the mass ratio of (low 10 molecular weight polyethylene oxide+hydroxypropylmethyl cellulose): admixed enteric polymer is in the range 1:2-6:1.
- 20. A formulation as claimed in claim 19, wherein the mass ratio of (low molecular weight polyethylene oxide+hydroxypropylmethyl cellulose): admixed enteric polymer is in the range 1:2-2:1.15
- 21. A formulation as claimed in any one of claims 12-20, wherein the enteric coating makes up 2-15% by weight of the formulation.
- 22. A formulation as claimed in claim 21, wherein the enteric coating makes Op 5-10% by weight of the formulation.
- 23. The use of low molecular weight polyethylene oxide in an oral controlled-release 20 pharmaceutical formulation, having a hydroxypropylmethyl ceiiuiose matrix, to enhance the erosion of the matrix after a predetermined period of time following administration of the formulation to a patient.AP/F7 96 / 00883
- 24. The use as claimed in claim 23, wherein the predetermined period of time is 6 hours.
- 25 25. A process for the production of a pharmaceutical formulation as defined in claim 1, which comprises mixing: an active drug compound; low molecular weight polyethylene oxide; hydroxypropylmethyl cellulose; tabletting excipients; and optionally one or more enteric polymers; followed by pressing into tablets.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523752.5A GB9523752D0 (en) | 1995-11-21 | 1995-11-21 | Pharmaceutical formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9600883A0 AP9600883A0 (en) | 1997-01-31 |
AP718A true AP718A (en) | 1999-01-06 |
Family
ID=10784188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1996/000883A AP718A (en) | 1995-11-21 | 1996-11-21 | A controlled-release pharmaceutical formulation for oral administration. |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0862437A1 (en) |
JP (1) | JPH10513481A (en) |
KR (1) | KR19990071505A (en) |
CN (1) | CN1215993A (en) |
AP (1) | AP718A (en) |
AR (1) | AR004335A1 (en) |
AU (1) | AU709560B2 (en) |
BG (1) | BG102438A (en) |
BR (1) | BR9611626A (en) |
CA (1) | CA2232715A1 (en) |
CO (1) | CO4480020A1 (en) |
CZ (1) | CZ155498A3 (en) |
GB (1) | GB9523752D0 (en) |
HR (1) | HRP960554A2 (en) |
HU (1) | HUP9903734A3 (en) |
IS (1) | IS4706A (en) |
MA (1) | MA26410A1 (en) |
MX (1) | MX9804008A (en) |
NO (1) | NO982302L (en) |
NZ (1) | NZ322053A (en) |
OA (1) | OA10687A (en) |
PE (1) | PE22898A1 (en) |
PL (1) | PL326981A1 (en) |
SK (1) | SK63098A3 (en) |
TN (1) | TNSN96141A1 (en) |
TR (1) | TR199800902T2 (en) |
WO (1) | WO1997018814A1 (en) |
YU (1) | YU62096A (en) |
ZA (1) | ZA969722B (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ504487A (en) * | 1997-12-16 | 2002-11-26 | Pfizer Prod Inc | Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence |
CA2320900C (en) | 1998-03-19 | 2009-10-27 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
GT199900061A (en) * | 1998-05-15 | 2000-10-14 | Pfizer | PHARMACEUTICAL FORMULATIONS. |
EP0987020A1 (en) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
EP0974343B1 (en) * | 1998-07-22 | 2004-09-29 | Pharma Pass II LLC | Process for manufacturing a solid metoprolol composition |
CO5140079A1 (en) * | 1998-10-14 | 2002-03-22 | Novartis Ag | PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT |
UA67802C2 (en) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION |
US20030059467A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Pharmaceutical composition comprising doxasozin |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2005037247A2 (en) * | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Oral matrix formulations of doxazosin |
US20050255157A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
KR100574554B1 (en) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | Sustained release composition for oral administration of niacin |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
KR100679111B1 (en) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | A sustained release tablet comprising doxazosin |
RU2442574C2 (en) * | 2005-08-22 | 2012-02-20 | Новартис Аг | THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
ES2360423T3 (en) | 2006-04-26 | 2011-06-03 | Supernus Pharmaceuticals, Inc. | OXCARBAZEPIN CONTROLLED RELEASE PREPARATIONS THAT HAVE SIGMOIDAL RELEASE PROFILE. |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
UA97244C2 (en) | 2006-05-04 | 2012-01-25 | Берингер Ингельхайм Интернациональ Гмбх | Polymorphs of 1-((4-methyfquinazolin-2-yl)methyl)-3-methyl-7- (2-butyn-1-yl)-8-(3-(r)-aminopiperidin-l-yl)xanthine |
CN100396282C (en) * | 2006-07-25 | 2008-06-25 | 山东省医药工业研究所 | Slow released doxazosin mesilate capsule and its prepn process |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2262484B1 (en) | 2008-03-11 | 2013-01-23 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
PE20140960A1 (en) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
KR20190016601A (en) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment for diabetes in patients inappropriate for metformin therapy |
TWI478712B (en) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | Pharmaceutical composition for modified release |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101004205B1 (en) * | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | The controlled released pharmaceutical compsitions of udenafil for sustained release property |
EP3711751A1 (en) | 2009-02-13 | 2020-09-23 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
AU2010239311B2 (en) | 2009-04-20 | 2014-05-22 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
KR20190071840A (en) | 2009-11-27 | 2019-06-24 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
ES2935300T3 (en) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | combitherapy |
CA2804926C (en) | 2010-07-09 | 2019-01-08 | James Trinca Green | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
JP2013540156A (en) | 2010-10-19 | 2013-10-31 | エルセリクス セラピューティクス インコーポレイテッド | Chemosensory receptor ligand based therapy |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
EA039943B1 (en) | 2011-01-07 | 2022-03-30 | Анджи Фарма (Юс) Элэлси | Method for lowering blood glucose levels in a subject |
CN102058555A (en) * | 2011-01-13 | 2011-05-18 | 北京汇诚瑞祥医药技术有限公司 | Doxazosin controlled release tablet |
AR085689A1 (en) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR |
CN102188431A (en) * | 2011-05-09 | 2011-09-21 | 浙江九旭药业有限公司 | Doxazosin mesylate sustained-release tablets and preparation method thereof |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP3003297A4 (en) | 2013-06-05 | 2017-04-19 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
JP6615109B2 (en) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Medical use of DPP-4 inhibitors |
CN105616378A (en) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | Fluconazole capsule and preparation method therefor |
EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2123291A (en) * | 1982-07-06 | 1984-02-01 | Lepetit Spa | Suloctidil compositions |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
WO1992001445A1 (en) * | 1990-07-23 | 1992-02-06 | Alza Corporation | Oral osmotic device for delivering nicotine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
-
1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
-
1996
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Application Discontinuation
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
-
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2123291A (en) * | 1982-07-06 | 1984-02-01 | Lepetit Spa | Suloctidil compositions |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
WO1992001445A1 (en) * | 1990-07-23 | 1992-02-06 | Alza Corporation | Oral osmotic device for delivering nicotine |
Also Published As
Publication number | Publication date |
---|---|
MX9804008A (en) | 1998-09-30 |
BG102438A (en) | 1999-01-29 |
EP0862437A1 (en) | 1998-09-09 |
CN1215993A (en) | 1999-05-05 |
NO982302D0 (en) | 1998-05-20 |
OA10687A (en) | 2002-11-27 |
AR004335A1 (en) | 1998-11-04 |
WO1997018814A1 (en) | 1997-05-29 |
TNSN96141A1 (en) | 2005-03-15 |
PE22898A1 (en) | 1998-05-07 |
GB9523752D0 (en) | 1996-01-24 |
JPH10513481A (en) | 1998-12-22 |
IS4706A (en) | 1998-03-31 |
BR9611626A (en) | 1999-06-01 |
AP9600883A0 (en) | 1997-01-31 |
TR199800902T2 (en) | 1998-09-21 |
CA2232715A1 (en) | 1997-05-29 |
ZA969722B (en) | 1998-05-20 |
HRP960554A2 (en) | 1998-02-28 |
AU709560B2 (en) | 1999-09-02 |
HUP9903734A3 (en) | 2000-04-28 |
HUP9903734A2 (en) | 2000-03-28 |
PL326981A1 (en) | 1998-11-09 |
CZ155498A3 (en) | 1999-03-17 |
AU7572196A (en) | 1997-06-11 |
NO982302L (en) | 1998-07-17 |
KR19990071505A (en) | 1999-09-27 |
CO4480020A1 (en) | 1997-07-09 |
YU62096A (en) | 1999-03-04 |
SK63098A3 (en) | 1999-05-07 |
NZ322053A (en) | 1999-11-29 |
MA26410A1 (en) | 2004-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP718A (en) | A controlled-release pharmaceutical formulation for oral administration. | |
JP2528130B2 (en) | Oral dosage form sustained release pharmaceutical composition | |
TWI469781B (en) | Use of binders for manufacturing storage stable formulations | |
AU2002249881B2 (en) | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | |
AU741361B2 (en) | Modified release matrix formulation of cefaclor and cephalexin | |
JP5517932B2 (en) | Improved formulation of lamotrigine | |
AU2003260336C1 (en) | Sustained release formulations comprising lamotrigine | |
JP5420590B2 (en) | pH independent extended release pharmaceutical composition | |
KR101858797B1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO1995021607A1 (en) | Controlled release hydrogel formulation | |
EP2726064B1 (en) | Controlled release oral dosage form comprising oxycodone | |
HU226589B1 (en) | Tegaserod pharmaceutical compositions | |
US20130059003A1 (en) | Sustained release donepezil formulations | |
BG107372A (en) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | |
US20030133978A1 (en) | Pharmaceutical formulations | |
WO2006103551A1 (en) | Controlled release formulations of oxycodone | |
KR20070094110A (en) | Controlled release formulation | |
WO2008044111A1 (en) | Pharmaceutical formulation tablet | |
WO2009087663A2 (en) | Oral controlled release coated tablet | |
EP1434570B1 (en) | Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline | |
US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
WO2000001364A1 (en) | Stable pharmaceutical compositions of thieno [3,2-c] pyridine derivatives | |
WO2005037247A2 (en) | Oral matrix formulations of doxazosin | |
GB2334212A (en) | Modified release matrix formulation for cefaclor and cephalexin |